Copyright
©The Author(s) 2020.
World J Nephrol. Jun 30, 2020; 9(1): 1-8
Published online Jun 30, 2020. doi: 10.5527/wjn.v9.i1.1
Published online Jun 30, 2020. doi: 10.5527/wjn.v9.i1.1
Encephalopathy |
Uraemic encephalopathy |
Dialysis disequilibrium syndrome |
Aluminium encephalopathy |
Reversible posterior encephalopathy syndrome |
Metabolic derangement |
Hyponatremia |
Hypocalcemia |
Hypomagnesemia |
Immunosuppression neurotoxicity |
Tacrolimus (FK-506) |
Cyclosporin |
High dose corticosteroids |
CNS infections |
Meningitis |
Encephalitis |
Abscess |
Drug toxicity |
Quinolone antibiotics (e.g., Ciprofloxacin) |
Beta Lactams (e.g., Penicillin, Mezlocillin, Cephalosporins) |
Antidepressants |
Bupropion HCL |
Cerebrovascular disease |
Subdural haematoma |
Cerebral infarct |
Intracerebral haemorrhage |
Co-existing epilepsy |
Primary CNS lymphoma |
Action myoclonus – renal failure syndrome |
Acute onset generalised tonic clonic seizure | |
Monitor ABC | |
IV Lorazepam 2 mg | |
Post seizure | Persistent seizure or recurrent seizures without regaining consciousness follow status epilepticus protocol |
Eliminate or correct identified provocative factors | |
Neurologic examination, EEG, MRI brain | |
If all negative, monitor without AED | |
If any positive (Neurologic examination abnormal or EEG – Epileptic activity or MR structural lesion) OR spontaneous recurrence when monitoring without AED -> then Initiate AED |
GFR (mL/min) | 60-90 | 30-60 | 15-30 | < 15 | Haemodialysis |
Levetiracetam | 500-1000 mg BD | 250-750 mg BD | 250-500 mg BD | 500-1000 mg OD | Plus 250-500 mg/d |
Toparimate | 50% decrease | 50% decrease | 50% decrease | 50-100 mg after HD | |
Zonisamide | 100-400 mg | 100-400 mg | |||
Oxcarbazepine | 300-600 mg BD | 300-600 mg BD | 300 mg/d starting dose | NA | NA |
Esclicarbazepine | None | 400-600 mg OD | 400-600 mg OD | ||
Clobazam | None | None | None | NA | None |
Pregabalin | None | 50% decrease | 25-125 mg/d | 25-75 mg /d | 25-150 mg after HD |
Lacosamide | None | None | 300 mg/d | Plus < 50% after HD | |
Rufinamide | None | None | None | NA | Plus 30% after HD |
Vigabatrin | 25% decrease | 50% decrease | 75% decrease | NA | NA |
Tiagabine | None | None | None | None | None |
Lamotrigine | None | None | None | None | NA |
Phenytoin | None | None | None | None | May need in high flux HD |
Carbamazepine | None | NA | NA | 75% dose | Plus 75% after HD |
Valproate | None | None | None | None | May need in high flux HD |
Perampanel | None | None | NA | NA | NA |
Brivaracetam | None | None | NA | NA | None |
- Citation: Sawhney H, Gill SS. Renal transplant recipient seizure practical management. World J Nephrol 2020; 9(1): 1-8
- URL: https://www.wjgnet.com/2220-6124/full/v9/i1/1.htm
- DOI: https://dx.doi.org/10.5527/wjn.v9.i1.1